Concord Biotech Gets US FDA Nod for Arthritis Treatment Drug; Shares Up 4%
MT Newswires Live
Yesterday
Concord Biotech (NSE:CONCORDBIO, BOM:543960) has received approval from the US Food and Drug Administration (US FDA) for its Tofacitinib Tablets in strengths of 5 mg and 10 mg, according to a Wednesday filing to the Indian stock exchanges.
Tofacitinib tablets are used to treat adult patients with active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.
The statement quoted market estimates to show that the US market for Tofacitinib Tablets of both strengths combined is around $500 million.
The company's shares were up nearly 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.